Alkermes plc ALKS

NAS: ALKS | ISIN: IE00B56GVS15   30/04/2025
28,77 USD (0,00%)
(0,00%)   30/04/2025

1 mei 2025 · Alkermes plc Reports First Quarter 2025 Financial Results · Persbericht

30 april 2025 · New Survey Provides Insights into Diagnosis and Treatment Journey for People Living With Alcohol Use Disorder (AUD) · Persbericht

17 april 2025 · Alkermes to Report First Quarter Financial Results on May 1, 2025 · Persbericht

2 april 2025 · Alkermes to Participate in the 24th Annual Needham Virtual Healthcare Conference · Persbericht

1 april 2025 · Alkermes Announces Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia · Persbericht

27 maart 2025 · New National Survey of Healthcare Providers Offers Insights Into the Dynamic and Challenging Treatment Journey for People Living With Schizophrenia or Bipolar I Disorder · Persbericht

13 september 2024 · Alkermes Announces Launch of 7th Annual Alkermes Pathways Research Awards® Program · Persbericht

28 augustus 2024 · Alkermes to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference · Persbericht

22 augustus 2024 · Alkermes Announces Initiation of Vibrance-2 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 2 · Persbericht

24 juli 2024 · Alkermes plc Reports Second Quarter 2024 Financial Results · Persbericht

17 juli 2024 · Alkermes to Report Second Quarter Financial Results on July 24, 2024 · Persbericht

3 juni 2024 · Alkermes Presents Data From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 1 at SLEEP 2024 · Persbericht

29 mei 2024 · Alkermes to Participate in Two Upcoming Investor Conferences · Persbericht

28 mei 2024 · Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024 · Persbericht

14 mei 2024 · Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences · Persbericht

2 mei 2024 · Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk · Persbericht

1 mei 2024 · Alkermes plc Reports First Quarter 2024 Financial Results · Persbericht

24 april 2024 · Alkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1 · Persbericht

17 april 2024 · Alkermes to Report First Quarter Financial Results on May 1, 2024 · Persbericht

9 april 2024 · Alkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic Hypersomnia · Persbericht

Mijn selecties